Identifying appropriate patients for PLUVICTO is more important than ever. AIM for PLUVICTO even earlier for your patients with PSMA+ mCRPC.1,2
After your patients with PSMA+ mCRPC receive their first ARPI, be ready for what's next.1 Be ready to rethink the sequence.*
*For patients considered appropriate to delay taxane-based chemotherapy.1
Identifying Patients
AIM for PLUVICTO even earlier in mCRPC1,2
1 ARPI could have been received at any point in your patient’s prostate cancer journey, including in the castration-sensitive setting1,2
Patient Profiles
Meet patients with PSMA+ mCRPC who are eligible for PLUVICTO
Plan for PLUVICTO after only 1 ARPI, which could have been received at any point in your patient’s journey1,2
Robert, 68
Received 1 ARPI in the mHSPC setting
- Localized prostate cancer: Radical prostatectomy
- 4 years - BCR occurred (nmHSPC): Monitoring for 12 months
- mCRPC: ADT + ARPI for 21 months
- PSA began to rise: Diagnosed with PSMA+ mCRPC
Has bone and lymph node metastases with asymptomatic disease
James, 70
Received 1 ARPI in the mCRPC setting
- Localized prostate cancer: EBRT
- 2 years - BCR occurred (nmHSPC): ADT for 2 years
- mCRPC: ADT + ARPI for 11 months
- PSA began to rise: PSMA-PET shows positive disease
Has bone and lymph node metastases with mildly symptomatic disease
Hypothetical patient cases.
ADT, androgen deprivation therapy; BCR, biochemical recurrence; EBRT, external beam radiation therapy; mHSPC, metastatic hormone-sensitive prostate cancer; nmHSPC, nonmetastatic hormone-sensitive prostate cancer; PET, positron emission tomography; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen.
Advancing PLUVICTO Therapy for the Right Patients
Care Team Perspectives for a Patient With Metastatic APMN/S Prostate Cancer (mHSPC) Who Received an ARPI and Recently Progressed to Metastatic APMR Prostate Cancer (mCRPC)
Planning Ahead for PLUVICTO for Patients With Metastatic APMR Prostate Cancer (mCRPC)
Identifying Progression in Patients With Metastatic APMR Prostate Cancer (mCRPC) to Plan Ahead for PLUVICTO
Optimizing Treatment in Metastatic APMR Prostate Cancer (mCRPC) Beyond ARPI
Acting Early for Patients With Metastatic APMR Prostate Cancer (mCRPC)
Plan for PLUVICTO
Get Your Patients on PLUVICTO Promptly After Only 1 ARPI1
3 ways to accelerate the PLUVICTO referral process
*There are over 833 PLUVICTO treatment sites in the US. Please note that the PLUVICTO Treatment Centers listed are only those that have authorized their participation on the PLUVICTO website.4
†Primary plans only; an additional 1-2 days if secondary plan coverage review is required.
Which of your patients with PSMA+ mCRPC could benefit from PLUVICTO now?